Opiant Pharmaceuticals Announces Completion of Enrollment in Phase 2 Clinical Trial of OPNT002, Nasal Naltrexone, in Patients with Alcohol Use Disorder
Opiant launched its Phase 2 clinical study of OPNT002 for the treatment of alcohol use disorder in January 2022.
- Opiant launched its Phase 2 clinical study of OPNT002 for the treatment of alcohol use disorder in January 2022.
- Clinical and preclinical studies have shown that alcohol releases endorphins, which are the brains endogenous opioids.
- Alcohol use disorder is a chronic relapsing brain disease characterized by compulsive use of alcohol and the inability to control intake.
- Epidemiology of DSM-5 Alcohol Use Disorder: Results From the National Epidemiologic Survey on Alcohol and Related Conditions III.